Eshrati Babak, Baradaran Hamid Reza, Moradi Ghobad, Dehghanbanadaki Hojat, Azh Nima, Soheili Marzieh, Moetamed Gorji Nogol, Moradi Yousef
Preventive Medicine and Public Health Research Center, Iran University of Medical Sciences, Tehran, Iran.
Ageing Clinical & Experimental Research Team, Institute of Applied Health Sciences, University of Aberdeen, UK.
Med J Islam Repub Iran. 2021 Nov 1;35:144. doi: 10.47176/mjiri.35.144. eCollection 2021.
The evaluation of reinfection and the genetic structure of all human and virus genomes could help to develop programs and protocols for providing services and ultimately to prevent the disease by producing more effective vaccines. Therefore, the aim of this study was to investigate the presence and occurrence of COVID-19 reinfection through a narrative review study. We searched the Medline (PubMed), Embase, Scopus, Web of Science, Cochrane library, Ovid, and CINHAL databases. Inclusion criteria included all studies whose main purpose was to provide information about the occurrence or presence of reinfection in patients with COVID-19. An independent samples t test was used to compare the continuous outcomes between the 2 groups. The mean duration of the first episode in the group with mild or moderate COVID-19 was 24.42±1.67 days, and it was 21.80±3.79 days in the group with severe COVID-19. The mean duration of the second episode (reinfection) in patients with mild or moderate form was 15.38 ± 5.57 days, and it was 19.20±2.98 days in patients with severe form. In both episodes, the duration of the disease did not significantly differ between the 2 groups (p=0.484 in the first episode; p=0.675 in the second episode), but the interval to the occurrence of reinfection in patients with the mild or moderate form was significantly longer than those with the severe form (p<0.001). In this instance, the time interval in patients with the mild or moderate form was 36.63±5.71 days while in those with the severe form of the disease it was 29.70±5.65 days. Besides, the genomes of the viruses isolated from the first and second episode were different. According to the results, all patients should be very careful about the severity of the second episode because of the more need for medical interventions for saving the patients. The interval between the first end and the second episode as well as the duration of each episode is highly important for better management of the disease.
评估再感染情况以及所有人和病毒基因组的遗传结构,有助于制定提供服务的计划和方案,并最终通过生产更有效的疫苗来预防疾病。因此,本研究的目的是通过叙述性综述研究来调查新冠病毒再感染的存在情况和发生率。我们检索了Medline(PubMed)、Embase、Scopus、Web of Science、Cochrane图书馆、Ovid和CINHAL数据库。纳入标准包括所有主要目的是提供有关新冠病毒患者再感染发生率或存在情况信息的研究。采用独立样本t检验比较两组之间的连续结果。轻度或中度新冠患者第一病程的平均持续时间为24.42±1.67天,重度新冠患者为21.80±3.79天。轻度或中度形式患者第二病程(再感染)的平均持续时间为15.38±5.57天,重度形式患者为19.20±2.98天。在两个病程中,两组之间疾病持续时间无显著差异(第一病程p = 0.484;第二病程p = 0.675),但轻度或中度形式患者再感染发生的间隔时间显著长于重度形式患者(p<0.001)。在这种情况下,轻度或中度形式患者的时间间隔为36.63±5.71天,而重度形式疾病患者为29.70±5.65天。此外,从第一病程和第二病程分离出的病毒基因组不同。根据结果,由于拯救患者更需要医疗干预,所有患者都应非常关注第二病程的严重程度。第一病程结束与第二病程之间的间隔以及每个病程的持续时间对疾病的更好管理非常重要。